Supernus Sues Lupin to Block Copies of Trokendi XR Epilepsy Drug

Sept. 13, 2021, 6:13 PM

Supernus said Lupin’s proposed generic versions of Trokendi XR infringe 10 patents related to the drug, used to treat seizures and prevent migraines.

  • Supernus is seeking court order blocking copies until patents have expired and cash compensation if copies are made before then, according to complaint filed Friday in federal court in Wilmington, Delaware
  • Nine patents expire in November 2027 and one in April 2028: FDA Orange Book
  • Trokendi XR is an antiepileptic drug used to treat partial-onset or primary generalized tonic-clonic seizures and to prevent migraines
  • Supernus sued Ajanta in March and Torrent in July alleging infringement of ...

To read the full article log in. To learn more about a subscription click here.